ALK and non-small cell lung carcinoma: Despite its promising efficacy, crizotinib‐pretreated patients ultimately develop progressive disease (PD) by acquiring resistance after less than 1 year as a result of secondary ALK mutations or activation of alternative oncogenic pathways.5, 6 Continuing crizotinib therapy beyond progressive disease (CBPD) may also impact survival outcomes and may provide an ongoing survival benefit for patients with advanced ALK‐positive NSCLC.7, 8 However, how CBPD will contribute to the efficacy of crizotinib in the real‐world clinical practice was unclear.